Título:
Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey
Otros títulos:
Coordinador:
Director:
Compilador:
Autor:
Badgery, Henry E.
Muhlen-Schulte, Tjuntu
Zalcberg, John Raymond
D'souza, Bianka
Gerstenmaier, Jan F.
Pickett, Craig
Samara, Jaswinder Singh
Croagh, Daniel G.
Ahmed, Farhan
Allan, Emel
Amelina, Inna
Aroori, Somaiah
Balendran, Nalayini
Chu, Linda C.H.
Carnelli, Carlos
Muhlen-Schulte, Tjuntu
Zalcberg, John Raymond
D'souza, Bianka
Gerstenmaier, Jan F.
Pickett, Craig
Samara, Jaswinder Singh
Croagh, Daniel G.
Ahmed, Farhan
Allan, Emel
Amelina, Inna
Aroori, Somaiah
Balendran, Nalayini
Chu, Linda C.H.
Carnelli, Carlos
Tutor:
Tipo de documento:
Artículo
Editor:
Palabras clave:
Descriptores:
NEOPLASIAS PANCREÁTICAS
PRONÓSTICO
TERAPÉUTICA
TOMOGRAFÍA
PRONÓSTICO
TERAPÉUTICA
TOMOGRAFÍA
Año de publicación:
2023
Contenido:
Resumen:
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poor prognosis.
Accurate preoperative assessment using computed tomography (CT) to determine resectability is
crucial in ensuring patients are offered the most appropriate therapeutic strategy. Despite the use of
classification guidelines, any interobserver variability between reviewing surgeons and radiologists may
confound decisions influencing patient treatment pathways.
Methods: In this multicentre observational study, an international group of 96 clinicians (42 hepatopancreatobiliary
surgeons and 54 radiologists) were surveyed and asked to report 30 pancreatic CT
scans of pancreatic cancer deemed borderline at respective multidisciplinary meetings (MDM). The
degree of interobserver agreement in resectability among radiologists and surgeons was assessed and
subgroup regression analysis was performed.
Results: Interobserver variability between reviewers was high with no unanimous agreement. Overall
interobserver agreement was fair with a kappa value of 0.32 with a higher rate of agreement among
radiologists over surgeons.
Conclusion: Interobserver variability among radiologists and surgeons globally is high, calling into
question the consistency of clinical decision making for patients with PDAC and suggesting that central
review may be required for studies of neoadjuvant or adjuvant approaches in future as well as ongoing
quality control initiatives, even amongst experts in the field.
Descripción:
metadata.articulos.dc.description.uri:
Editorial:
Elsevier
EN:
HPB. Nov. 2023;25(11):1393-1401
Financiadores:
Citación:
Badgery H, Muhlen-Schulte T, Zalcberg J y otros. Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey. HPB [en línea] . Nov. 2023;25(11):1393-1401
Citación:
metadata.articulos.cc.license.name:
ISBN:
e-ISBN:
ISSN:
1477-2574
ISMN:
Otros identificadores:
Cobertura geográfica:
Cobertura temporal:
Departamento académico:
Grupo de investigación:
Licencia:
Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)
Colecciones:
| Ficheros | Descripción | Tamaño | Formato | ||
|---|---|---|---|---|---|
| Determination of borderline resectable pancreatic cancer.pdf | Determination of borderline resectable pancreatic cance | 767.56 KB | Adobe PDF |